Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b) Effective August 20, 2009, Nicholas Stergis resigned as a director of Adeona Pharmaceuticals, Inc.

(d) On August 21, 2009, Adeona Pharmaceuticals, Inc. (the "Company") appointed Max Lyon, the Company's current President and Chief Executive Officer, to the Company's Board of Directors. Mr. Lyon has not been, nor at the time of this disclosure is expected to be, named to any committees of the board of directors.

Mr. Lyon has agreed that in the event he no longer continues to serve as both President and Chief Executive Officer of Adeona, if requested by resolution of the board, he will resign his position from the board of directors. Other than such agreement and the arrangements with Mr. Lyon set forth in his employment agreement, a copy of which was filed as Exhibit 10.1 to the Company's periodic filing on Form 8-K filed on July 2, 2009, there are no plans or arrangements, compensatory or otherwise, between the Company and Mr. Lyon.

There are no arrangements or understandings between Mr. Lyon and any person with respect to his appointment to the Company's board of directors. Additionally, there have been no transactions involving Mr. Lyon that would require disclosure under Item 404(a) of Regulation S-K.

---